MedTrace Logo

Study of NM8074 in Adult C3 Glomerulopathy Patients

NCT05647811 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-13

No results posted yet for this study

Summary

This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.

Conditions

  • C3 Glomerulopathy

Interventions

DRUG

NM8074

NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.

Sponsors & Collaborators

  • NovelMed Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-05-31
Primary Completion
2029-08-31
Completion
2030-07-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05647811 on ClinicalTrials.gov